Appia is a Columbia University academic spin-out that employs a lean biotech model using certified contract organizations, academic collaborations and a team of expert consultants and financial officers.

A large portfolio of patents covers both composition of matter and indications ranging from cancer to neurodegeneration.

Our team is investigating a family of proprietary compounds that reverses abnormal epigenetic modifications found in certain cancer cells as well as cells undergoing neurodegenerative processes.

.